Dongkook Drug to hold customer sale after Madeca Cream tops 87 million in cumulative sales
Dongkook Drug said Wednesday it will run a “Madeca Cream Customer Appreciation Sale” through Feb. 28 to mark cumulative sales of 87 million units of its Centellian24 derma-cosmetic flagship product, Madeca Cream.
The promotion will be offered on the company’s official online store, DK SHOP, under two themes: a Lunar New Year gift event and a “Find the right Madeca Cream for my skin” campaign.
Through Feb. 18, the Lunar New Year gift event will offer discounts of up to 87% on best-selling products including Madeca Cream Tight Lifting, Expert Madeca Mela Capture Ampoule Max and Madeca Cream, and provide a 100,000-won coupon pack. DK SHOP will also give gifts based on purchase totals of 30,000 won, 50,000 won and 70,000 won or more, and run events including a first-purchase welcome deal and a lucky-bag New Year’s cash drawing.
Through Feb. 28, the “Find the right Madeca Cream for my skin” promotion will sell a 9,900-won kit that lets customers try multiple versions at once, including Madeca Cream Time Reverse Zero, Madeca Cream Power Boosting Formula, Madeca Cream Hydra Calming and Madeca Cream Tight Lifting. New members will receive coupons worth up to 30,000 won, and DK SHOP will also hold a review event for the “NEW Aging Focus Cream.”
Hanmi Pharmaceutical says FDA grants breakthrough therapy designation for congenital hyperinsulinism drug
Hanmi Pharmaceutical said Wednesday that the U.S. Food and Drug Administration has granted breakthrough therapy designation to efpeglucagon, its treatment candidate for congenital hyperinsulinism.
The designation is intended to speed development and review for drugs targeting serious or life-threatening conditions when early clinical evidence suggests a meaningful improvement over existing therapies. Breakthrough therapy drugs receive intensive guidance and support, and may qualify for rolling review, allowing portions of an application to be submitted and reviewed as they are completed.
Congenital hyperinsulinism is a rare disease in which excessive insulin secretion causes hypoglycemia. Hanmi said no FDA-approved treatment has been approved specifically for the condition.
Hanmi is developing efpeglucagon as a once-weekly formulation. The company said an interim analysis from a global Phase 2 trial last year showed favorable safety and tolerability and a marked reduction in both hypoglycemia and severe hypoglycemia. The global Phase 2 trial is ongoing, with results expected in the second half of this year.
Yuyu Pharma makes strategic investment in U.K. freeze-dried pet food company James & Ella
Yuyu Pharma said Wednesday it has made a strategic investment in James & Ella, a U.K. premium freeze-dried pet food company.
The company described James & Ella as a leading player in the U.K. freeze-dried pet food category. It sells through major retail channels including Waitrose, Ocado and Amazon, and also operates a direct-to-consumer subscription channel.
Yuyu said demand for freeze-dried nutrition products is rising in the pet market, driven by interest in premium ingredients suitable for human consumption, high digestibility and veterinary-based products. The investment is part of Yuyu’s global expansion strategy in the pet wellness market.
Yuyu said it plans to build an animal-industry portfolio spanning veterinary biologics, sustainable food-system technologies, and pet nutrition and community models.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.